BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Overview of personalized medicine in the disease genomic era

  • Hong, Kyung-Won (Department of Biomedical Engineering, School of Medicine, Kyung Hee University) ;
  • Oh, Berm-Seok (Department of Biomedical Engineering, School of Medicine, Kyung Hee University)
  • Accepted : 2010.08.04
  • Published : 2010.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Sir William Osler (1849-1919) recognized that "variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions we know as disease". Accordingly, the traditional methods of medicine are not always best for all patients. Over the last decade, the study of genomes and their derivatives (RNA, protein and metabolite) has rapidly advanced to the point that genomic research now serves as the basis for many medical decisions and public health initiatives. Genomic tools such as sequence variation, transcription and, more recently, personal genome sequencing enable the precise prediction and treatment of disease. At present, DNA-based risk assessment for common complex diseases, application of molecular signatures for cancer diagnosis and prognosis, genome-guided therapy, and dose selection of therapeutic drugs are the important issues in personalized medicine. In order to make personalized medicine effective, these genomic techniques must be standardized and integrated into health systems and clinical workflow. In addition, full application of personalized or genomic medicine requires dramatic changes in regulatory and reimbursement policies as well as legislative protection related to privacy. This review aims to provide a general overview of these topics in the field of personalized medicine.

Keywords

References

  1. Xing, J., Watkins, W. S., Shlien, A., Walker, E., Huff, C. D., Witherspoon, D. J., Zhang, Y., Simonson, T. S., Weiss, R. B., Schiffman, J. D., Malkin, D., Woodward, S. R. and Jorde, L. B. (2010) Toward a more uniform sampling of human genetic diversity: a survey of worldwide populations by high-density genotyping. Genomics, (in press).
  2. Ku, C. S., Loy, E. Y., Salim, A., Pawitan, Y. and Chia, K. S. (2010) The discovery of human genetic variations and their use as disease markers: past, present and future. J. Hum. Genet. 55, 403-415. https://doi.org/10.1038/jhg.2010.55
  3. Manolio, T. A., Brooks, L. D. and Collins, F. S. (2008) A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118, 1590-1605. https://doi.org/10.1172/JCI34772
  4. Abrahams, E., Ginsburg, G. S. and Silver, M. (2005) The personalized medicine coalition: goals and strategies. Am. J. Pharmacogenomics 5, 345-355. https://doi.org/10.2165/00129785-200505060-00002
  5. Heikes, K. E., Eddy, D. M., Arondekar, B. and Schlessinger, L. (2008) Diabetes risk calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care 31, 1040-1045. https://doi.org/10.2337/dc07-1150
  6. Liu, J., Wyatt, J. C. and Altman, D. G. (2006) Decision tools in healthcare: focus on the problem, not the solution. BMC Med. Inform. Decis. Mak. 6, 4. https://doi.org/10.1186/1472-6947-6-4
  7. Hariri, S., Yoon, P. W., Moonesinghe, R., Valdez, R. and Khoury, M. J. (2006) Evaluation of family history as a risk factor and screening tool for detecting undiagnosed diabetes in a nationally representative survey population. Genet. Med. 8, 752-759. https://doi.org/10.1097/01.gim.0000250205.73963.f3
  8. Feero, W. G., Bigley, M. B. and Brinner, K. M. (2008) New standards and enhanced utility for family health history information in the electronic health record: an update from the American Health Information Community's Family Health History Multi-Stakeholder Workgroup. J. Am. Med. Inform. Assoc. 15, 723-728. https://doi.org/10.1197/jamia.M2793
  9. Willard, H. (2009) Organization, variation, and expression of the human genome as a foundation of genomic and personalized medicine; in Genomics and personalized medicine. Willard, H., and Ginsburg, G. S. (eds.), pp. 4-22, Elsevier, San Diego, CA.
  10. Hawkins, R. D., Hon, G. C. and Ren, B. (2010) Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11, 476-486. https://doi.org/10.1038/nrg2795
  11. Carenini, M. (2009) ReMINE: an ontology-based risk management platform. Stud. Health Technol. Inform. 148, 32-42.
  12. Huang, E. and Huang, A. (2009) Breast cancer and genomic medicine; in Genomics and personalized medicine, Willard, H., and Ginsburg, G. S. (eds.), pp. 869-878, Elsevier, San Diego, CA.
  13. Wiesner, G., Slavin, T. and Barnholtz-Sloan, J. (2009) Colorectal cancer; in Genomics and personalized medicine, Willard, H., and Ginsburg, G. S. (eds.), pp. 879-897, Elsevier, San Diego, CA.
  14. Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E. J., Greiner, T. C., Weisenburger, D. D., Rosenwald, A., Ott, G., Muller-Hermelink, H. K., Gascoyne, R. D., Delabie, J., Rimsza, L. M., Braziel, R. M., Grogan, T. M., Campo, E., Jaffe, E. S., Dave, B. J., Sanger, W., Bast, M., Vose, J. M., Armitage, J. O., Connors, J. M., Smeland, E. B., Kvaloy, S., Holte, H., Fisher, R. I., Miller, T. P., Montserrat, E., Wilson, W. H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W. C. and Staudt, L. M. (2006) Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 354, 2431-2442. https://doi.org/10.1056/NEJMoa055759
  15. Voora, D., McLeod, H. L., Eby, C. and Gage, B. F. (2005) The pharmacogenetics of coumarin therapy. Pharmacogenomics 6, 503-513. https://doi.org/10.2217/14622416.6.5.503
  16. Ross, J. S., Schenkein, D. P., Pietrusko, R., Rolfe, M., Linette, G. P., Stec, J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L. and Hortobagyi, G. N. (2004) Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122, 598-609. https://doi.org/10.1309/5CWPU41AFR1VYM3F
  17. Metzker, M. L. (2010) Sequencing technologies - the next generation. Nat. Rev. Genet. 11, 31-46. https://doi.org/10.1038/nrg2626
  18. Service, R. F. (2006) Gene sequencing. The race for the $1,000 genome. Science 311, 1544-1546. https://doi.org/10.1126/science.311.5767.1544
  19. Hunter, D. J., Khoury, M. J. and Drazen, J. M. (2008) Letting the genome out of the bottle--will we get our wish? N. Engl. J. Med. 358, 105-107. https://doi.org/10.1056/NEJMp0708162
  20. Clifton, J. M., VanBeuge, S. S., Mladenka, C. and Wosnik, K. K. (2010) The Genetic Information Nondiscrimination Act 2008: what clinicians should understand. J. Am. Acad. Nurse Pract. 22, 246-249. https://doi.org/10.1111/j.1745-7599.2010.00504.x
  21. Vastag, B. (2006) New clinical trials policy at FDA. Nat. Biotechnol. 24, 1043. https://doi.org/10.1038/nbt0906-1043
  22. Botkin, J. R., Teutsch, S. M., Kaye, C. I., Hayes, M., Haddow, J. E., Bradley, L. A., Szegda, K. and Dotson, W. D. (2010) Outcomes of interest in evidence-based evaluations of genetic tests. Genet. Med. 12, 228-235. https://doi.org/10.1097/GIM.0b013e3181cdde04
  23. Batchelder, K. and Miller, P. (2006) A change in the market--investing in diagnostics. Nat. Biotechnol. 24, 922-926. https://doi.org/10.1038/nbt0806-922
  24. Ginsburg, G. S. and Willard, H. F. (2009) Genomic and personalized medicine: foundations and applications. Transl. Res. 154, 277-287. https://doi.org/10.1016/j.trsl.2009.09.005

Cited by

  1. Towards a personalized risk assessment for exposure of humans to toxic substances vol.24, pp.2, 2016, https://doi.org/10.1590/1414-462X201600020135
  2. Future perspectives of personalized medicine in traditional Chinese medicine: A systems biology approach vol.20, pp.1-2, 2012, https://doi.org/10.1016/j.ctim.2011.10.007
  3. Sequencing and analysis of a South Asian-Indian personal genome vol.13, pp.1, 2012, https://doi.org/10.1186/1471-2164-13-440
  4. Acute lung injury and acute respiratory distress syndrome: a genomic perspective vol.35, pp.6, 2011, https://doi.org/10.1016/j.medine.2011.02.003
  5. State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response vol.1, pp.3, 2013, https://doi.org/10.1007/s40142-013-0022-6
  6. Personalized Medicine in a New Genomic Era: Ethical and Legal Aspects vol.23, pp.4, 2017, https://doi.org/10.1007/s11948-016-9828-4
  7. Lesión pulmonar aguda y síndrome de distrés respiratorio agudo: una perspectiva genómica vol.35, pp.6, 2011, https://doi.org/10.1016/j.medin.2011.02.002
  8. Genetic testing: predictive value of genotyping for diagnosis and management of disease vol.2, pp.2, 2011, https://doi.org/10.1007/s13167-011-0077-y
  9. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era vol.31, pp.3, 2015, https://doi.org/10.1016/j.tig.2015.01.004
  10. Personalized medicine: a patient - centered paradigm vol.9, pp.1, 2011, https://doi.org/10.1186/1479-5876-9-206
  11. Downsizing genomic medicine: Approaching the ethical complexity of whole-genome sequencing by starting small vol.13, pp.3, 2011, https://doi.org/10.1097/GIM.0b013e31820f603f
  12. Design and implementation of the canadian kidney disease cohort study (CKDCS): A prospective observational study of incident hemodialysis patients vol.12, pp.1, 2011, https://doi.org/10.1186/1471-2369-12-10
  13. Whole-genome and whole-exome sequencing in neurological diseases vol.8, pp.9, 2012, https://doi.org/10.1038/nrneurol.2012.148
  14. A Quantitative Analysis of the Mass Media Coverage of Genomics Medicine in China: A Call for Science Journalism in the Developing World vol.18, pp.4, 2014, https://doi.org/10.1089/omi.2013.0108
  15. Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia vol.21, pp.12, 2017, https://doi.org/10.1089/omi.2017.0136